Ken Griffin Biogen Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $23.6 Million - $29.7 Million	-111,100 Reduced 45.8%	131,500 $28.4 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $1.02 Million - $1.23 Million	-4,600 Reduced 1.86%	242,600 $62.8 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $31.6 Million - $35.6 Million	-124,600 Reduced 33.51%	247,200 $63.5 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $42 Million - $48.6 Million	-152,700 Reduced 29.11%	371,800 $106 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $90.1 Million - $103 Million	-351,100 Reduced 40.1%	524,500 $146 Million

Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $132 Million - $160 Million	-522,700 Reduced 37.38%	875,600 $242 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $164 Million - $226 Million	843,600 Added 152.08%	1,398,300 $373 Million

1,046

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.